0
2020
Cancer Biomarkers Market

Cancer Biomarkers Market

by Profiling Technology (Omic Technologies, Imaging Technologies, Immunoassays, and Cytogenetics Based Tests), Biomolecule (Genetic Biomarkers, Protein Biomarkers, and Glyco-biomarkers), Cancer Type (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Stomach Cancer, and Others), and Application (Diagnostics, Drug Discovery and Development, Prognostics, Risk Assessment, and Others): Global Opportunity Analysis and Industry Forecast, 2020-2027
Update Available On-Demand

Report Code: A01124
Pages: 338
Apr 2020 | 17351 Views
Author(s) : Sahil Sinha, Ravi Telugunta , Onkar Sumant
Tables: 151
Charts: 68
  • Formats*:

  • Single User License, Five User
    License & Enterprise User License

  • Data Pack Excel License

  • It comes with the additional cost
    of $2500.00 contact sales.

 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Cancer Biomarkers Market

Request Now !

The cancer biomarkers market was valued at $10,944.08 million in 2019, and is projected to reach $26,979.50 million by 2027, registering a CAGR of 11.8% from 2020 to 2027.Cancer biomarkers are traceable substances or molecules that indicate the existence of cancerous cells in the body.The prevention of cancer by diagnosing and analyzing various cancer biomarkers using different diagnostic techniques is a profound approach to obtain rapid results for treatment. There are various types of biomarkers such as proteins, peptides, antibodies, and nucleic acids. Presence of these biomarkersin tissues, urine, serum, blood, and other body fluids indicate an abnormal process or a disease. Various such biomarkers for cancer indications have been studied and are used as biomarkers for diagnostics, prognostics, personalized medicines, and surrogate endpoints.The identification of different types of biomarkers is an integral part of various industries such as healthcare and pharmaceuticals. 

Cancer-Biomarker-Market-2020-2027

The global cancer biomarkers market is expected to witness a significant growth during the forecast period due to increase in prevalence of various types of cancers such as breast, prostate, and lung cancer. In addition, surge in importance of biological & targeted drug therapies, technological advancements, accuracy, and reliability of cancer biomarkers also contribute toward the growth of the market. Moreover, increase in investments from governments and public & private sector toward R&D for cancer diagnostics have a positive impact on the market. However, high cost of drug development, threat of failure associated with cancer treatment, and unregulated government regulations and reimbursement policies hamper the cancer biomarkers market growth. In contrast, advancements of cancer research and significant unmet need for cancer diagnosis are anticipated to provide new opportunities for the cancer biomarkers market.

Global Cancer Biomarkers Market Segmentation

The market is segmented on the basis ofprofiling technology, biomolecule, cancer type, application, and region. By profiling technology, it is classified intoomic technologies, imaging technologies, immunoassays, and cytogenetics-based tests. On the basis of biomolecule, it is segmented into genetic biomarkers, protein biomarkers, and glyco-biomarkers. By cancer type, it is categorized into breast cancer, lung cancer, prostate cancer, colorectal cancer, stomach cancer, and others.By application, it is segmented across diagnostics, drug discovery and development, prognostics, risk assessment, and others. Region-wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Profiling Technology Segment Review

By profiling technology, omic technologies and imaging technologies segments collectively accounted for 79.5% of the total market share in 2019, and is expected to exhibit a prominent growth rate in the future, owing to itsefficiency in early diagnosis of cancer. In addition,demand for safe and cost-effective drugs for treatment of cancer, developments in profilingtechnology, growth in healthcare expenditure, reduced cost in genome sequencing, and demand for effective diagnostics & therapeutic procedures for cancer are expected to further fuel the market growth.

Biomolecule Segment Review

By biomolecule, the genetic biomarkers segment dominated the cancer biomarkers market in 2019, and is anticipated to maintain its dominance during the forecast period. This is attributed to itsaccuracy to predict the stage of cancer, detect recurrence of cancers, and monitor effectiveness of treatments. In addition, biomarkers can be assayed in non-invasively collected biofluids like blood or serum anditfacilitates faster cancer diagnosis and early detection and screening of cancer. Moreover, cancer biomarkers, being subjected to dynamic modulation, can be used to enhance the understanding of efficacy, drug metabolism, drug action, and safety.

Cancer Biomarkers Market
By Profiling Technology

Your browser does not support the canvas element.

Omic technologies segment holds a dominant position in 2019 and would continue to maintain the lead over the forecast period.

Get more information on this report : Request Sample Pages

Cancer Type Segment Review

By cancer type, lung cancerdominated the cancer biomarkers market in 2019, and is anticipated to maintain its dominance during the forecast period. This is attributed to high incidences of lung cancer. However, the breast cancer segment is anticipated to grow at the fastest CAGR of 16.70% during the forecast period. This can be attributed to the increase in prevalence of breast cancer due to the adoption of unhealthy lifestyle, genetic profile of patients, growth in female geriatric population, and exposure to harmful radiations. 

Application Segment review

By application, the prognostics segment dominated the cancer biomarkers market in 2019, and is anticipated to maintain its dominance during the forecast period. This is attributed to its application in estimating the stage and severity of a cancer. However, the diagnostics segment is anticipated to grow at the fastest CAGR of 12.00%during the forecast period. Surge in incidences of cancer globally facilitates the demand for biomarkers, which leads to the growth of the cancer biomarkers market. 

Cancer Biomarkers Market
By Application

Your browser does not support the canvas element.

Diagnostics segment is projected as one of the most lucrative segment.

Get more information on this report : Request Sample Pages

North America accounted for majority of the market share in 2019, and is anticipated to continue this trend during the forecast period. This is attributed to the increased adoption of cancer biomarkers in the region. Moreover,high incidence rate of cancer in the regionpropels the market growth.In addition, variouscancer biomarker diagnostics are covered under health insurance in the region. However, Asia-Pacific is anticipated to grow at the fastest rate during the forecast period, owing to increase in incidence rate of cancer in China and Japan. Moreover, rise inawareness and affordability for advanced cancer treatmentsfurther drives the Asia-Pacific cancer biomarkers market.

Cancer Biomarkers Market
By Region

2027
North America 
Europe
Asia-pacific
Lamea

Asia-Pacific region would exhibit the highest CAGR of 15.1% during 2019-2026.

Get more information on this report : Request Sample Pages

Comprehensive competitive analysis and profiles of major market players such as, Abbott Laboratories, Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Company, Exact Sciences Corporation,F.Hoffmann-La Roche Ltd., Merck KGaA, PerkinElmer, Inc.,  Qiagen N.V., Siemens AG, and Thermo Fisher Scientific, Inc. are provided in this report. 

Key Benefits For Stakeholders

  • The cancer biomarkersmarket share and analysis is based on a comprehensive analysis of key developments in the cancer biomarkersindustry.
  • The development strategies adopted by the key cancer biomarkers market players are enlisted to understand the competitive scenario of the global market.
  • The study provides an in-depth analysis of the cancer biomarkersmarket trends to elucidate the imminent investment pockets.
  • The global market trends are studied from 2019 to 2027.
  • Information about key drivers, restrains, and opportunities and their impact analysis on the cancer biomarkersmarket size is provided.
  • Porter’s five forces analysis illustrates the potency of buyers and suppliers operating in the industry.
  • The quantitative analysis of the market from 2020 to 2027 is provided to determine the market potential.

Key Market Segments

By Profiling Technology

  • Omic Technologies
  • Imaging Technologies
  • Immunoassays
  • Cytogenetics-based Tests

By Biomolecule

  • Genetic Biomarkers
  • Protein Biomarkers
  • Glyco-biomarkers

By Cancer Type

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Stomach Cancer
  • Others

By Application

  • Diagnostics
  • Drug Discovery and Development
  • Prognostics
  • Risk Assessment
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • United Arab Emirates
    • Rest of LAMEA
 

Loading Table Of Content...


 
 

Global cancer biomarkers market has witnessed huge technological innovations during the last decade, owing to high level of growth due to the rise in interest of physicians towards early detection of cancer. Detection of cancer using biomarkers is on a continuous rise at a high rate and is expected to dominate the cancer diagnostics market during the forecast period. Use of cancer detection techniques using biomarkers coupled with growth in number of cancer population supplements the growth of the cancer biomarkers market. 

Currently, cancer detection using biomarkers is dominant in developed regions owing to the high healthcare expenditure and favorable reimbursement policies. However, the demand for novel cancer biomarkers is expected to shift from developed regions to developing regions due to rise in healthcare expenditure and growth in awareness about cancer. Furthermore, regulatory support from the respective government authorities and active initiatives from leading companies to create awareness for cancer diagnosis are further expected to boost the market growth during the forecast period.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : + 44-845-528-1300
Email : help@alliedmarketresearch.com
 
FREQUENTLY ASKED QUESTIONS?

A. The total market value of cancer biomarkers market is $10,944.08 million in 2019.

A. The market value of cancer biomarkers market in 2019 is $12,383.23 million.

A. The base year is 2019 in cancer biomarkers market

A. Top companies such as, F. Hoffman-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Qiagen NV, and Bristol-Myers Squibb Company held a high market position in 2019. These key players held a high market postion owing to the strong geographical foothold in different regions.

A. Profiling technology segment is the most influencing segment owing to factors such as increase in popularity due to the growing role of precision and personalized medicine for cancer treatment and growth in healthcare expenditure. In addition, increase in prevalance of cancer also has increased the demand for advancement of the profiling technology. Hence, this is most influencing segment growing in cancer biomarkers market.

A. The major factor that fuels the growth of the global cancer biomarkers market includes rise in prevalence of cancer. This leads to surge in demand for cancer biomarkers which contribute to the growth of the market.

A. Asia-Pacific has the highest growth rate in the market which is growing due to the contribution of the following emerging countries such as India with a CAGR of 15.1%. This is due to improvement in health awareness, development in healthcare infrastructure, and rise in number of hospitals & diagnostic centers equipped with advanced medical facilities.

A. Cancer biomarkers refers to a substance or specific response of the body that can either be molecules that are secreted by tumor cells or processes that indicate the presence of cancer in the human body.

A. The cancer biomarkers are used in several applications including diagnostics, drug discovery and development, prognostics, risk assessment, and others. Several profiling technology and biomolecules are utilized to collect patient information to obtain accurate results that are used to treat and diagnose cancer.

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Request Free Sample
RELATED TAGS
 

HAVE QUESTIONS?
SPEAK WITH ANALYST

 

DID YOU MISS ANYTHING?
DO YOU HAVE SPECIFIC REQUIREMENTS?

 

Download Free Sample

OR

Purchase Full Report of
Cancer Biomarkers Market

Start reading instantly.
This Report and over 18,822+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,456
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
    (Apr 2021 - Apr 2022)
  • Data Pack
  • $3,840
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Apr 2021 - Apr 2022)
  • Single User
  • $5,769
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Apr 2021 - Apr 2022)
  • Five Users
  • $6,450
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Apr 2021 - Apr 2022)
  • Enterprise
    License/PDF

  • $10,995
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
    (Apr 2021 - Apr 2022)
  • Library
    Membership

  • $ 999
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers